Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Multiple Myeloma 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 115Lenalidomide 74daratumumab 57Bortezomib 52carfilzomib 41Calcium Dobesilate 36pomalidomide 35Cyclophosphamide 26isatuximab 23belantamab mafodotin 22Specimen Handling 20Biopsy 20Magnetic Resonance Spectroscopy 17dexamethasone acetate 13dexamethasone 21-phosphate 13auricularum 12ixazomib 11iberdomide 11fludarabine 11elotuzumab 11selinexor 10Melphalan 10fludarabine phosphate 8talquetamab 7X-Rays 7trametinib 6nirogacestat 6venetoclax 5Thalidomide 5Nuclear Medicine Department, Hospital 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Multiple Myeloma × High-Throughput Screening Assays × Clear all
NCT03389347 2026-05-08

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

University of Washington

Phase NA Active not recruiting
40 enrolled 7 charts
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡